The apparent smaller effect on mortality in carriers of BRCA2 PGVs compared to BRCA1 PGVs may be due to the lower risk of ovarian cancer in carriers of BRCA2 PGVs as well as the more aggressive biological characteristics of BRCA1-associated BC [55,65,66,67,68,69,70,71]. The gene discussed is BRCA2; the disease is ovarian carcinoma.